生物活性：Crisaborole-d4 is deuterium labeled Crisaborole. Crisaborole (AN-2728) is a potent inhibitor of PDE4 and cytokine release; inhibit PDE4 with an IC50 of 0.49 μM.
体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
瑞禧生物 has not independently confirmed the accuracy of these methods. They are for reference only.
Crisaborole-d4 相关抗体:
PDE1B Antibody (YA1553)
PDE4B Antibody (YA2932)
PDE2A Antibody (YA2989)
PDE4D Antibody (YA1714)
分子量：255.07
Formula：C14H6D4BNO3
CAS 号：2268785-42-6
非标记 CAS：906673-24-3
性状：固体
颜色：Off-white to light yellow
中文名称：克瑞沙硼-d4；克立硼罗-d4
运输条件：Room temperature in continental US; may vary elsewhere.
储存方式：-20°C, protect from light
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
纯度 & 产品资料
含量： 98.8%
参考文献
[1]. Nazarian R, et al. AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. Curr Opin Investig Drugs. 2009 Nov;10(11):1236-42.
 [Content Brief]
[2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
 [Content Brief]
[3]. Akama T, et al. Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2129-32.
 [Content Brief]